Best available therapy

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MortalityChronic Graft Versus Host DiseaseRelapsing Multiple Sclerosis

49 competitors in Mortality

#DrugCompanyPhaseTrials

1

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

102

Lovenox

Sanofi

Approved

13

Aldactone

Pfizer

Approved

14

Coly-Mycin M

PParkedale

Approved

25

Zocor

OOrganon and Co

Approved

16

Venofer

AAmerican Regent, Inc.

Approved

17

Merrem

BB. Braun Medical Inc.

Approved

18

ZINPLAVA

Merck & Co.

Approved

19

Mounjaro

Eli Lilly

Phase 3

110

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

2Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Myelofibrosis6 trials

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Active, not recruiting·AbbVie·Phase 3·NCT04468984·330 enrolled

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Terminated·NS Pharma·Phase 2·NCT04854096·7 enrolled

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Unknown status·KKartos Therapeutics, Inc.·Phase 2/3·NCT03662126·385 enrolled

Show 3 more trials

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Terminated·CCTI BioPharma·Phase 3·NCT01773187·327 enrolled

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Completed·Novartis·Phase 3·NCT00934544·219 enrolled

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor

Active, not recruiting·GGeron Corporation·Phase 3·NCT04576156·327 enrolled

Infections2 trials

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

Completed·MMelinta Therapeutics, Inc.·Phase 3·NCT02168946·77 enrolled

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

Completed·Pfizer·Phase 3·NCT01644643·345 enrolled

Polycythemia Vera2 trials

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

Completed·Novartis·Phase 3·NCT02038036·149 enrolled

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

Completed·AAOP Orphan Pharmaceuticals AG·Phase 3·NCT02218047·170 enrolled

Essential Thrombocythemia2 trials

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Completed·Bristol-Myers Squibb·Phase 3·NCT03952039·202 enrolled

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Completed·—·Phase 3·NCT02101268·156 enrolled

Enterobacteriaceae Infections1 trial

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

Recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07089186·80 enrolled

8 more indications

Acute Graft Vs. Host Disease1 trial

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Completed·Novartis·Phase 3·NCT02913261·310 enrolled

Thrombocytopenia1 trial

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

Terminated·CCTI BioPharma·Phase 3·NCT02055781·311 enrolled

Mortality1 trial

Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria

Completed·MMaimónides Biomedical Research Institute of Córdoba··NCT04167228·348 enrolled

Acinetobacter Baumannii1 trial

Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Not yet recruiting·BBioVersys AG·Phase 2·NCT07431307·120 enrolled

Treatment1 trial

Calcifediol in the Treatment of COVID 19

Completed·MMaimónides Biomedical Research Institute of Córdoba··NCT05819918·728 enrolled

Severe Infection1 trial

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Completed·Shionogi·Phase 3·NCT02714595·152 enrolled

Relapsing Multiple Sclerosis1 trial

A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT04047628·156 enrolled

Chronic Graft Versus Host Disease1 trial

A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

Active, not recruiting·Incyte·Phase 3·NCT06821542·9 enrolled

Details

Drug Info

Related News